Sofinnova Investments, Inc. Blueprint Medicines Corp Transaction History

Sofinnova Investments, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $13.3 Million - $27 Million	-245,182 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $5.97 Million - $7.34 Million	63,322 Added 34.82%	245,182 $26.3 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $14.7 Million - $19.9 Million	181,860 New	181,860 $18.7 Million
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $6.31 Million - $8.8 Million	-94,891 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$57.09 - $79.27 $1.81 Million - $2.52 Million	31,791 Added 50.38%	94,891 $7.4 Million
Q1 2020 May 13, 2020	BUY	$48.11 - $82.22 $3.04 Million - $5.19 Million	63,100 New	63,100 $3.69 Million
Q2 2019 Aug 13, 2019	SELL	$73.54 - $97.8 $5.29 Million - $7.03 Million	-71,866 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $3.5 Million - $6.22 Million	71,866 New	71,866 $5.75 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $2.34 Million - $3.81 Million	-51,339 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$58.91 - $78.32 $2.41 Million - $3.2 Million	-40,861 Reduced 44.32%	51,339 $4.01 Million
Q2 2018 Nov 15, 2018	BUY	$60.96 - $101.18 $5.04 Million - $8.37 Million	82,701 Added 870.63%	92,200 $5.85 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $579,059 - $961,108	9,499 New	9,499 $603,000

352

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.21B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.